CURE

FDA Application Submitted for Rusfertide Treatment in Polycythemia Vera

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...
Targeted Oncology

NDA for Rusfertide Submitted to FDA for Polycythemia Vera

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...
Pharmaceutical Technology on MSN

Takeda and Protagonist seek FDA approval for rusfertide to treat PV

Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and ...
The American Journal of Managed Care

Managing Polycythemia Vera to Reduce Risks and Improve Lives

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. In this interview, Andrew Kuykendall, MD, ...

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif., January 05, 2026--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist") announced the submission of a New Drug ...
Healio

Rusfertide reduces hematocrit without phlebotomy in polycythemia vera

Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...
CURE

Rusfertide Maintains Hematocrit Control in Patients With Polycythemia Vera

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 ...
Yahoo Finance

Polycythemia Vera Market Insight, Epidemiology and Market Forecast, 2034: JAKAFI & BESREMi Lead Polycythemia Vera Market, But New Therapies Poised to Disrupt by 2034

Dublin, Feb. 17, 2025 (GLOBE NEWSWIRE) -- The "Polycythemia Vera - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report ...
Medscape

Aspirin effective for polycythemia vera

Rome, Italy - A new double-blind, placebo-controlled study has shown that low-dose aspirin can prevent thrombotic complications in patients with polycythemia vera, provided they have no ...
Pharmabiz

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera: Osaka, Japan Wednesday, January 7, 2026, 17:00 Hrs [IST] Takeda, focused on c ...
Mena FN

Polycythemia Vera Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, And Companies

DelveInsight's, “Polycythemia Vera Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Polycythemia Vera pipeline landscape. It covers the ...
Monthly Prescribing Reference

Rusfertide Improves Hematocrit Control in Patients With Polycythemia Vera

Findings showed 77% of PV patients treated with rusfertide achieved a clinical response compared with 33% of those who received placebo. Topline data were announced from a phase 3 trial evaluating ...